Abstract
A series of levosimendan analogues were designed and synthesized, employing the Friedel–Crafts reaction, hydrolysis, and cyclization from the key intermediate compound R(−)-6-(4-aminophenyl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone, which was obtained from the starting material, acetanilide. These compounds, except 1b, exhibited potent anti-congestive heart failure activities, especially the compounds 1e and 1k, which showed more effective action than levosimendan.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abouzid KAM, Khalil NA, Ahmed EM et al (2009) Structure-based molecular design, synthesis, and in vivo anti-inflammatory activity of pyridazinone derivatives as nonclassic COX-2 inhibitors. Med Chem Res. doi:10.1007/s00044-009-9218-4
Ali MA, Yar MS (2007) Synthesis and antimycobacterial activity of novel 4-[5-(substituted phenyl)-1-phenyl-4,5-dihydro-1H-3-pyrazolyl]-2-methyl phenol derivatives. Med Chem Res 15:463–470. doi:10.1007/s00044-007-9000-4
Austel V, Herder J, Eberlein W et al (1982) Pyridazinone-substituted benzimidazoles and salts. US Patent 4361563
Bäckström RJ, Haarala JV, Honkanen EJ et al (1992) (−)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-hydrazono]propanedinitrile. UK Patent 2251615A
Bansal R, Kumar D, Carron R et al (2009) Synthesis and vasodilatory activity of some amide derivatives of 6-(4-carboxymethyloxyphenyl)-4,5-dihydro-3(2H)-pyridazinone. Eur J Med Chem. doi:10.1016/j.ejmech.2009.06.006
Bristol JA, Sircar L, Moos WH et al (1984) 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem 27(9):1099–1103
Cherng SC, Huang WH, Shiau CY et al (2006) Mechanisms of antiplatelet activity of PC-90, a newly synthesized pyridazinone derivative. Eur J Pharmacol 532:32–37
Gottdiener JS, Arnold AM, Aurigemma GP et al (2000) Predictors of congestive heart failure in the elderly: the cardiovascular health study. JACC 35(6):1628–1637
Hayes JS, Pollock GD, Wilson H et al (1987) Pharmacology of LY195115, a potent, orally active cardiotonic with a long drug of action. J Cardiovasc Pharmacol 9:425–434
Hosenpud JD (1999) Levosimendan, a novel myofilament calcium sensitizer, allows weaning of parenteral inotropic therapy in patients with severe congestive heart failure. Am J Cardiol 83:9(I)–11(I)
Krum H, Liew D (2003) New and emerging drug therapies for the management of acute heart failure. Intern Med J 33(11):515–520
McCullough PA, Philbin EF, Spertus JA et al (2002) Confirmation of a heart failure epidemic: findings from the Resource Utilization among Congestive Heart Failure (REACH) study. J Am Coll Cardiol 39(1):60–69
Nieminen MS, Bohm M, Cowie MR et al (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the task force on acute heart failure of the European Society of Cardiology. Eur Heart J 26(4):384–416
Nobuo M, Seiichi U, Hiroo M (1993) Cardiovascular effects of NSP-804 and NSP-805, novel cardiotonic agents with vasodilator properties. J Cardiovasc Pharmacol 21(6):983–995
Thota S, Bansal R (2009) Synthesis of new pyridazinone derivatives as platelet aggregation inhibitors. Med Chem Res. doi:10.1007/s00044-009-9232-6
Acknowledgment
This study was supported by the Scientific Research Startup Foundation of the Chinese Ministry of Education for Returnees (jiaowaisiliu[2007]1108).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, L., Zhou, H., Yang, B. et al. Synthesis and anti-congestive heart failure activity of novel levosimendan analogues. Med Chem Res 20, 287–292 (2011). https://doi.org/10.1007/s00044-010-9319-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-010-9319-0